CIMG Inc.

CIMG Inc. is a Nevada-based company that sources, markets, and distributes health and wellness products—including Maca-based dietary supplements, functional foods, beauty products, and AI-powered computing hardware—primarily across Asia. The company transitioned from specialty coffee to its current focus in mid-2024, launching the Homology of Medicine and Food Series (e.g., exosome eye drops) and Computing Power Product Series (GPU-integrated AI modules) alongside its Maca Series. For the fiscal year ended September 30, 2025, it generated $10.3 million in revenue, with 98.6% attributable to these three product lines; however, it reported a net loss of $4.89 million and held only $45,356 in cash as of December 31, 2025. The company is offering up to 900,000,000 units—each comprising one share of common stock and one warrant—at $0.015 per unit, for gross proceeds of up to $13.5 million in the initial closing. Proceeds will be used to fund working capital, operating expenses, taxes, and general corporate purposes, including potential acquisitions. CIMG’s business model relies on wholesale distribution, digital marketing, and third-party manufacturing, while holding 730 Bitcoin ($63.98 million) as a major asset. It is pursuing this S-1 registration to raise capital amid recurring losses, negative working capital, and substantial doubt about its ability to continue as a going concern—highlighting urgent liquidity needs and strategic transformation.

Key Takeaways